ES2212304T3 - Agente radioprotector para peptidos marcado con un radioisotopo. - Google Patents

Agente radioprotector para peptidos marcado con un radioisotopo.

Info

Publication number
ES2212304T3
ES2212304T3 ES98928875T ES98928875T ES2212304T3 ES 2212304 T3 ES2212304 T3 ES 2212304T3 ES 98928875 T ES98928875 T ES 98928875T ES 98928875 T ES98928875 T ES 98928875T ES 2212304 T3 ES2212304 T3 ES 2212304T3
Authority
ES
Spain
Prior art keywords
povidone
composition
composition according
peptide
radioisotope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98928875T
Other languages
English (en)
Spanish (es)
Inventor
Dan Shochat
Albert S. K. Chan
Michael J. Buckley
David Colcher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Coulter Pharmaceutical Inc
Original Assignee
Coulter Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coulter Pharmaceutical Inc filed Critical Coulter Pharmaceutical Inc
Application granted granted Critical
Publication of ES2212304T3 publication Critical patent/ES2212304T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ES98928875T 1997-06-03 1998-06-03 Agente radioprotector para peptidos marcado con un radioisotopo. Expired - Lifetime ES2212304T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4838797P 1997-06-03 1997-06-03
US48387P 1997-06-03
US08/918,525 US5961955A (en) 1997-06-03 1997-08-21 Radioprotectant for peptides labeled with radioisotope
US918525 1997-08-21

Publications (1)

Publication Number Publication Date
ES2212304T3 true ES2212304T3 (es) 2004-07-16

Family

ID=26726075

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98928875T Expired - Lifetime ES2212304T3 (es) 1997-06-03 1998-06-03 Agente radioprotector para peptidos marcado con un radioisotopo.

Country Status (14)

Country Link
US (2) US5961955A (enExample)
EP (1) EP1003560B1 (enExample)
JP (1) JP4291417B2 (enExample)
AT (1) ATE249845T1 (enExample)
AU (1) AU743823B2 (enExample)
CA (1) CA2290987A1 (enExample)
DE (1) DE69818272T2 (enExample)
DK (1) DK1003560T3 (enExample)
ES (1) ES2212304T3 (enExample)
IL (1) IL133271A (enExample)
NO (1) NO315693B1 (enExample)
NZ (1) NZ502029A (enExample)
PT (1) PT1003560E (enExample)
WO (1) WO1998055154A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5961955A (en) * 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
JP2002516883A (ja) * 1998-06-02 2002-06-11 ザ ダウ ケミカル カンパニー 近接照射療法のための放射性ヨウ素化フェノール
US20020102208A1 (en) * 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
KR100330733B1 (ko) * 1999-11-30 2002-04-03 노광 폴리에틸렌글리콜포스페이트, 그의 합성방법 및 그를방사능보호제로 사용하는 방법
WO2002022000A2 (en) * 2000-09-15 2002-03-21 Sloan Kettering Institute For Cancer Research Targeted alpha particle therapy using actinium-225 conjugates
HUP0304083A2 (hu) * 2001-02-26 2004-03-29 Bristol-Myers Squibb Pharma Company Radiofarmakon kompozíciók, előállításuk és eljárás radiofarmakonok pufferolására
US6972324B2 (en) * 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
US7238338B1 (en) * 2001-06-22 2007-07-03 Triumf System and method for the large scale labeling of compounds with radiohalogens
US7344702B2 (en) 2004-02-13 2008-03-18 Bristol-Myers Squibb Pharma Company Contrast agents for myocardial perfusion imaging
WO2003105762A2 (en) * 2002-06-14 2003-12-24 Actinium Pharmaceuticals Ltd. Treating disease using radium-225
US7018614B2 (en) * 2002-11-05 2006-03-28 Eastern Isotopes, Inc. Stabilization of radiopharmaceuticals labeled with 18-F
MXPA05005558A (es) 2002-11-26 2005-07-26 Protein Design Labs Inc Anticuerpos quimericos y humanizados para integrina ( 5 ( 1 que modulan la angiogenesis.
EP1444990A1 (en) * 2003-02-07 2004-08-11 Amersham plc Improved Radiometal Complex Compositions
US7485283B2 (en) * 2004-04-28 2009-02-03 Lantheus Medical Imaging Contrast agents for myocardial perfusion imaging
JP5230865B2 (ja) 2004-07-15 2013-07-10 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ結合性化合物
DK1851200T3 (da) 2005-02-25 2014-04-14 Tetralogic Pharm Corp Dimere iap-inhibitorer
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
AU2006279929A1 (en) * 2005-08-09 2007-02-22 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
EP2049563B1 (en) * 2006-07-24 2014-03-12 Tetralogic Pharmaceuticals Corporation Dimeric iap antagonists
JP5452223B2 (ja) * 2006-07-24 2014-03-26 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ阻害剤
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014238A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100113326A1 (en) * 2006-07-24 2010-05-06 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
EP2116241B1 (en) 2007-01-26 2016-04-27 Pola Pharma Inc. Pharmaceutical composition
EP2136832B1 (en) 2007-03-26 2015-09-02 General Regeneratives Limited Methods for promoting protection and regeneration of bone marrow using cxcl9 and anti-cxcl9 antibodies
AU2009220244B2 (en) 2008-02-29 2014-10-09 Lantheus Medical Imaging, Inc. Contrast agents for applications including perfusion imaging
TW201021831A (en) * 2008-11-17 2010-06-16 Genentech Inc Method and formulation for reducing aggregation of a macromolecule under physiological conditions
CN102458396B (zh) 2009-04-15 2017-05-10 兰休斯医疗成像公司 使用抗坏血酸稳定化放射性药物组合物
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
EP3323810B1 (en) 2010-02-08 2022-01-05 Lantheus Medical Imaging, Inc. Automated reaction system, cassette and apparatus for synthesizing imaging agents
GB201013808D0 (en) * 2010-08-18 2010-09-29 Ge Healthcare Ltd Peptide radiotracer compositions
AU2013203000B9 (en) 2012-08-10 2017-02-02 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
AU2014216515A1 (en) * 2013-02-15 2015-10-08 Thomas Jefferson University Kit for tumor imaging
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
EP3094391B1 (en) * 2014-01-17 2024-11-20 Repligen Corporation Sterilizing chromatography columns
IL237852A0 (en) 2015-03-19 2016-03-24 Yeda Res & Dev Antibodies against amphigoline, medical preparations containing them and their use
TWI799366B (zh) * 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
WO2017155937A1 (en) * 2016-03-07 2017-09-14 Actinium Pharmaceuticals, Inc. Stabilized radiolabeled anti-cd45 immunoglobulin compositions
US11339221B2 (en) 2017-11-01 2022-05-24 Tufts Medical Center, Inc. Bispecific antibody constructs and methods of use
WO2020219550A1 (en) * 2019-04-23 2020-10-29 Amgen Inc. The use of low molecular weight polyvinylpyrrolidone (pvp) to reduce viscosity of high concentration protein formulations
US12043671B2 (en) 2021-06-16 2024-07-23 Gundersen Lutheran Medical Foundation, Inc. Antibodies targeting an amphiregulin-derived cell surface neo-epitope
US20250019350A1 (en) 2023-06-16 2025-01-16 Progenics Pharmaceuticals, Inc Synthesis of the prostate specific membrane antigen (psma) radiolabeled inhibitor [18f]dcfpyl

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE933885C (de) * 1952-06-22 1955-10-06 Helmut Richard Dr Kanitz Verfahren zur Herstellung kolloidaler Loesungen radioaktiver Metalle wie radioaktiver Goldisotope
US4421735A (en) * 1980-04-17 1983-12-20 The Massachusetts General Hospital Radiolabeled diagnostic compositions and method for making the same
US4427631A (en) * 1982-05-27 1984-01-24 Euroceltique, S.A. Povidone irradiation
US4411881A (en) * 1982-07-12 1983-10-25 New England Nuclear Corporation Composition and method for stabilizing radiolabeled compounds using thiocarbonylated diethylenetriamines
EP0111414A3 (en) * 1982-12-08 1985-05-02 Mallinckrodt, Inc. (a Delaware corporation) Radiographic imaging agents
US4676979A (en) * 1984-12-31 1987-06-30 Eastern Virginia Medical Authority/Med. Ctr. Hosp. Method of protecting animals against ionizing radiation
US5393512A (en) * 1985-01-14 1995-02-28 Vanderheyden; Jean-Luc Stable therapeutic radionuclide compositions and methods for preparation thereof
US5061641A (en) * 1988-04-01 1991-10-29 Immunomedics, Inc. Method for radiolabeling proteins
RO103925B1 (ro) * 1989-02-27 1992-04-26 Institutul De Chimie Macromoleculara "P.Poni" Derivat de polivinilpirolidona si procedeu de preparare
CA2066779A1 (en) * 1989-09-22 1991-03-23 Jean-Luc Vanderheyden Stable therapeutic radionuclide compositions and methods for preparation thereof
US5011676A (en) * 1990-03-27 1991-04-30 Thomas Jefferson University Method to directly radiolabel antibodies for diagnostic imaging and therapy
AU2541592A (en) * 1991-08-01 1993-03-02 Hybritech Incorporated Improvements in or relating to modified haptens useful as imaging and therapeutic agents
AU2462592A (en) * 1991-08-29 1993-04-05 Mallinckrodt Medical, Inc. Use of gentisic acid or gentisyl alcohol for stabilising radiolabeled peptides and proteins
ES2081717T5 (es) * 1992-04-30 2000-02-16 Amersham Int Plc Formulaciones de compuestos radiomarcados.
WO1994002174A1 (fr) * 1992-07-28 1994-02-03 Toray Industries, Inc. Immunocomplexe
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5961955A (en) * 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope

Also Published As

Publication number Publication date
NO995906L (no) 1999-12-03
JP2002516612A (ja) 2002-06-04
JP4291417B2 (ja) 2009-07-08
DE69818272T2 (de) 2004-07-01
WO1998055154A1 (en) 1998-12-10
US6338835B1 (en) 2002-01-15
DE69818272D1 (de) 2003-10-23
NO315693B1 (no) 2003-10-13
IL133271A (en) 2004-06-01
IL133271A0 (en) 2001-04-30
DK1003560T3 (da) 2003-12-01
EP1003560A1 (en) 2000-05-31
AU743823B2 (en) 2002-02-07
WO1998055154A9 (en) 1999-04-08
CA2290987A1 (en) 1998-12-10
US5961955A (en) 1999-10-05
NO995906D0 (no) 1999-12-02
AU8057098A (en) 1998-12-21
ATE249845T1 (de) 2003-10-15
EP1003560B1 (en) 2003-09-17
PT1003560E (pt) 2004-02-27
NZ502029A (en) 2001-12-21

Similar Documents

Publication Publication Date Title
ES2212304T3 (es) Agente radioprotector para peptidos marcado con un radioisotopo.
EP0670736B1 (en) Labelled interleukin-8 and medical uses thereof
Abrams et al. Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats
US5605671A (en) Radiolabeled neutrophil activating peptides for imaging
ES2204954T3 (es) Formadores de quelatos metalicos que contienen monoamina, diamida y tiol.
PL204239B1 (pl) Sposób znakowania promieniotwórczego proteiny lub peptydu za pomoca itru-90
CA2279349C (en) Ascorbate-stabilized radiopharmaceutical method and composition
van der Laken et al. Imaging of infection in rabbits with radioiodinated interleukin-1 (α and β), its receptor antagonist and a chemotactic peptide: a comparative study
Vaidyanathan et al. Improved xenograft targeting of tumor-specific anti-epidermal growth factor receptor variant III antibody labeled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate
US20100047167A1 (en) Combination therapy in the treatment of cancer
Shi et al. Potential therapeutic radiotracers: preparation, biodistribution and metabolic characteristics of 177Lu-labeled cyclic RGDfK dimer
Singh et al. A simplified kit for instant preparation of technerium-99m human immunoglobulin-G for imaging inflammatory foci
Ranson et al. Different radiolabelling methods alter the pharmacokinetic and biodistribution properties of Plasminogen Activator Inhibitor Type 2 (PAI-2) forms
US20240261445A1 (en) Precision radiopharmaceutical therapy of lymphoma and other diseases
RU2698101C2 (ru) Радиофармацевтическая композиция для терапии воспалительных заболеваний суставов на основе радионуклида 188Re и микросфер альбумина крови человека, а также состав и способ её получения
O'Donnell et al. Radioimmunotherapy of acquired immunodeficiency syndrome (AIDS) associated lymphoma
US20220288245A1 (en) Radiopharmaceutical compound and composition for positron emission tomography (pet) imaging of interleukin-2 receptor positive cells, process for the preparation thereof, related kit and uses thereof
Akgün et al. Radiopharmaceuticals and their quality control
PL224367B1 (pl) Farmaceutyczny zestaw na bazie gammaglobuliny ludzkiej normalnej